Document Detail

Clinical trial with an experimental taurine derivative, taltrimide, in epileptic patients.
MedLine Citation:
PMID:  3081338     Owner:  NLM     Status:  MEDLINE    
The antiepileptic effect, effects on EEG, and tolerability of taltrimide, a new taurine derivative, were studied in this open clinical trial in 27 patients with severe epilepsy resistant to conventional drugs. After the 2-week control phase, taltrimide was given in gradually increasing doses up to 4.0 g/day--this dose used for 12 days. Taltrimide was given over 4 weeks and it was gradually withdrawn over 2 weeks. The frequency of seizures increased statistically significantly during the trial with increasing dose of taltrimide and decreased again in the withdrawal phase of the trial. Of six dropouts, one had status epilepticus, and in two patients increased number or severity of seizures necessitated withdrawal of taltrimide. There were no changes in EEG recordings or in laboratory data for safety evaluation. Taltrimide penetrated well through the blood-brain barrier, with the concentration of its main metabolite, phthalimidoethanesulphonamide, in cerebrospinal fluid, about half that in serum. The concentration of phenytoin increased statistically significantly, and there was a significant decrease in serum carbamazepine concentration during the taltrimide treatment. The anticonvulsive effect of taltrimide observed in animal experiments could not be confirmed in this study; in contrast, the seizures increased statistically significantly during taltrimide treatment. The reason for this remains obscure. The doses used, the significant drug interactions, or the patient material seemingly do not explain totally the noticed increase in seizure frequency. One explanation may be that taltrimide has proconvulsive properties in humans.
K Koivisto; J Sivenius; T Keränen; J Partanen; P Riekkinen; G Gothoni; O Tokola; P J Neuvonen
Related Documents :
7718378 - Interactions between opioid drugs and propofol in laboratory models of seizures.
15591648 - Effect of mpep, a selective mglur5 antagonist, on the antielectroshock activity of conv...
1628588 - Interaction of the anticonvulsant ameltolide with standard anticonvulsants.
17270398 - Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- t...
10480018 - Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate s...
9652898 - Efficacy of a low-dose subcutaneous lisuride infusion in parkinson's disease.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Epilepsia     Volume:  27     ISSN:  0013-9580     ISO Abbreviation:  Epilepsia     Publication Date:    1986 Jan-Feb
Date Detail:
Created Date:  1986-03-28     Completed Date:  1986-03-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2983306R     Medline TA:  Epilepsia     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  87-90     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carbamazepine / blood,  therapeutic use
Clinical Trials as Topic
Clonazepam / blood,  therapeutic use
Epilepsy / blood,  drug therapy*
Indoles / blood,  therapeutic use*
Phenobarbital / blood,  therapeutic use
Phenytoin / blood,  therapeutic use
Valproic Acid / blood,  therapeutic use
Reg. No./Substance:
0/Indoles; 0/Phthalimides; 1622-61-3/Clonazepam; 298-46-4/Carbamazepine; 50-06-6/Phenobarbital; 57-41-0/Phenytoin; 81428-04-8/taltrimide; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nutritional influence on serum ammonia in young patients receiving sodium valproate.
Next Document:  Blood flow, PO2, PCO2 and pH during progressive working contractions in a whole muscle group.